ArticleClinical drug investigation2009
Quality and stability of ramipril generics/copies versus reference ramipril (Tritace): a 3-month stability comparative study.
Article in Clinical drug investigation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- Quality assessment of common anti-malarial medicines marketed in Gambella, National Regional State, South Western-Ethiopia.Malaria journal · 2024Article
- The quality of medical products for cardiovascular diseases: a gap in global cardiac care.BMJ global health · 2021Article
- Regulatory Compliance and Associated Quality of Amoxicillin in Drug Retail Outlets of Southwestern Ethiopia.Drug, healthcare and patient safety · 2021Article
- Quality of fixed dose artemether/lumefantrine products in Jimma Zone, Ethiopia.Malaria journal · 2019Article
- Substandard drugs: a potential crisis for public health.British journal of clinical pharmacology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the quality and stability over time of marketed ramipril generics/copies, in terms of Sanofi-Aventis specifications, relative to that of the reference ramipril product Tritace.
methodsThe quality and dissolution profiles of 22 marketed generic/copy tablet formulations of ramipril (2.5 mg) were compared with the reference ramipril tablet (2.5 mg; Tritace). Samples were analysed for levels of ramipril and impurities (as determined by the level of the major metabolite ramipril-diketopiperazine) before and after storage under temperature-stressed conditions (40 degrees C and 75% relative humidity) for 1.5 and 3 months. Dissolution analyses were performed before and after 3 months' temperature-stressed storage. All analytical results were compared with Sanofi-Aventis specifications for the manufacture of the reference ramipril product. One batch per generic/copy drug was analysed.
resultsIn terms of the level of ramipril, 24% (4/17) of generics/copies failed to meet reference ramipril specifications (90-105% of label claim) at baseline, increasing to 47% (8/17) after 3 months under stressed conditions. At baseline, the dissolution profiles of 24% (5/21) of generics/copies failed to meet the reference ramipril product specifications (>or=80% dissolved in 30 minutes), with the failure rate increasing to 57% (12/21) after storage for 3 months. Total levels of impurities were above reference ramipril product specifications (<or=5.0%) in 32% (7/22) of generics/copies at baseline, increasing to 68% (15/22) at 3 months. Overall, only 24% (5/21) of the generics/copies were of equivalent quality and showed similar dissolution profiles to that of the reference ramipril product.
conclusionsA significant percentage of ramipril generics/copies evaluated showed reduced quality, stability and solubility compared with the reference ramipril product (Tritace), thereby confirming the need for vigilance regarding the evaluation of generics/copies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.